Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium.

Nat Genet. 2002 May;31(1):55-9. Epub 2002 Apr 22.

PMID:
11967536
2.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P.

Cancer Res. 2003 Dec 1;63(23):8153-7.

3.

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H.

Am J Hum Genet. 2002 Aug;71(2):432-8. Epub 2002 Jul 28.

4.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

5.

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N; Breast Cancer Linkage Consortium.

Am J Hum Genet. 2003 Apr;72(4):1023-8. Epub 2003 Feb 27.

6.

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.

Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2008 Dec;112(3):569-73. doi: 10.1007/s10549-007-9878-z. Epub 2008 Jan 3.

PMID:
18175216
7.

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.

Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L.

Breast Cancer Res Treat. 2008 Jul;110(1):161-7. Epub 2007 Jul 28.

PMID:
17661168
8.

Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.

Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E.

Isr Med Assoc J. 2007 Nov;9(11):791-6.

9.

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.

Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H, Waisfisz Q.

J Med Genet. 2011 Dec;48(12):860-3. doi: 10.1136/jmedgenet-2011-100380. Epub 2011 Nov 5.

PMID:
22058428
10.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.

J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. Review.

PMID:
18172190
11.

Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.

Iniesta MD, Gorin MA, Chien LC, Thomas SM, Milliron KJ, Douglas JA, Merajver SD.

Cancer Genet Cytogenet. 2010 Oct 15;202(2):136-40. doi: 10.1016/j.cancergencyto.2010.07.124.

PMID:
20875877
12.

[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].

Pohlreich P, Kleibl Z, Kleiblová P, Janatová M, Soukupová J, Macháčková E, Házová J, Vašíčková P, Sťahlová Hrabincová E, Navrátilová M, Svoboda M, Foretová L.

Klin Onkol. 2012;25 Suppl:S59-66. Review. Czech.

PMID:
22920209
13.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
14.

Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.

Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ.

Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-7.

15.

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.

JAMA. 2006 Mar 22;295(12):1379-88.

PMID:
16551709
16.

Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.

Lindeman GJ, Hiew M, Visvader JE, Leary J, Field M, Gaff CL, Gardner RJ, Trainor K, Cheetham G, Suthers G, Kirk J.

Breast Cancer Res. 2004;6(4):R401-7. Epub 2004 Jun 2.

17.

German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.

Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA Network.

Eur J Cancer. 2005 Dec;41(18):2896-903. Epub 2005 Oct 18.

PMID:
16239104
18.

CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.

Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD, Bevan S, Bishop K, McGuire S, Houlston RS, Eeles RA.

Br J Cancer. 2002 Dec 2;87(12):1445-8.

19.

Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.

Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T, Wokolorczyk D, Jakubowska A, Serrano-Fernández P, Dork T, Narod SA, Lubinski J.

J Med Genet. 2009 Feb;46(2):132-5. doi: 10.1136/jmg.2008.061697. Epub 2008 Oct 17.

PMID:
18930998
20.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

Supplemental Content

Support Center